Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06277427
Status:
RECRUITING
Last Update Posted:
2024-02-26
First Post:
2024-02-01
Brief Title:
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Sponsor:
Lingli Dong
Organization:
Tongji Hospital
Study Overview
Official Title:
Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Lupus nephritis LN and ANCA-associated vasculitis are severe autoimmune diseases which may lead to the death of patients particularly when they are refractory to the conventional therapeutic agents Based on the current knowledge the autoantibodies against self-antigens may exert important pathological roles in the pathogenesis of both LN and ANCA-associated vasculitis of which the origins are primarily plasmablasts and plasma cells BCMA is the molecule expressed on memory B cells plasmablasts and plasma cells and therefore is an ideal target for the elimination of potential pathogenic antibody secreting cells Chimeric antigen receptor CAR T cells against BCMA may provide a novel therapeutic way for the refractory LN and ANCA-associated vasculitis patients to eliminate the pathogenic autoantibody-secreting cells In this study the safety and efficacy of a novel CAR-T cell therapy using PRG-1801 cells are evaluated in patients with refractory LN and ANCA-associated vasculitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None